Chemotherapy-induced Cardiotoxicity and Mitigation
29 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A retrospective nomogram development and validation study in a single centre with good discrimination metrics (AUROC 0.901) and internal validation, but based on a surrogate endpoint (elevated troponin) rather than hard clinical outcomes, limiting generalizability.
A Scientific Statement outlining quality standards and best practices for preclinical cardio-oncology research, intended to promote standardization, reproducibility, and rigor in the field.
A retrospective cohort study with adequate sample size and sound methodology demonstrating that myocardial work parameters detect cardiac dysfunction earlier than ejection fraction, but requiring prospective validation and external replication to confirm clinical utility.
Early mechanistic study combining in vivo rat toxicology with in vitro enzyme kinetics, lacking clinical endpoints, controls for confounding, or quantified effect sizes.
Early-stage preclinical study in an animal model demonstrating formulation optimization and proof-of-concept for a nanocarrier delivery strategy; lacks human efficacy data and clinical outcomes.
A narrative review synthesizing current evidence on circulating biomarkers in cardio-oncology, recommending multimodal assessment strategies but acknowledging gaps in validation and standardization rather than reporting new primary data.
A prospective single-centre cohort study with adjudicated endpoints and identified predictors of mid-term CV events, but limited by single-centre design and lack of a comparator arm, providing real results that require confirmation in larger populations.